drugset / Trial / NCT06378346

GU-01: Glycyrrhizin in Prostate Cancer

NCT06378346

Phase 2 Recruiting 60 enrolled University of Illinois at Chicago
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)

Timeline

Start
2024-07-25
Primary completion
2027-03
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycyrrhizin Unknown 75 mg Oral
Subject Glycyrrhizin Unknown 150 mg Oral

Indications